Skip to main content
45°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
0.6998
-0.0002 (-0.03%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Invivyd, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 19, 2023
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...
Via
Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
December 19, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
December 18, 2023
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Recap: Invivyd Q3 Earnings
November 09, 2023
Via
Benzinga
Invivyd's Earnings: A Preview
November 08, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Invivyd
June 23, 2023
Via
Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 18, 2023
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 18, 2023
Via
Benzinga
Crude Oil Rises 3%; US Housing Market Index Increases In December
December 18, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded up 0.14% to 37,356.29 while the NASDAQ rose 0.25% to 14,851.19. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Is COVID-19 Antibody Focused Invivyd Stock Trading Over 150% Higher Today?
December 18, 2023
Invivyd Inc (NASDAQ: IVVD) shares are trading higher after the company released initial results from the ongoing CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life...
Via
Benzinga
Exposures
COVID-19
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
December 18, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
October 31, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
September 11, 2023
Initial primary endpoint data anticipated in late 2023 or early Q1 2024
From
Invivyd
Via
GlobeNewswire
7 Biotech Stocks to Sell in September Before They Crash & Burn
September 06, 2023
These are just a few of the top biotech stocks to sell today - especially with each of the firms dealing with legitimate issues.
Via
InvestorPlace
Invivyd to Participate in Upcoming Investor Conferences
September 06, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Appoints William Duke as Chief Financial Officer
September 05, 2023
From
Invivyd
Via
GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
August 10, 2023
Via
Benzinga
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
August 10, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
July 27, 2023
From
Invivyd
Via
GlobeNewswire
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
July 21, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People
July 17, 2023
Invivyd Inc (NASDAQ: IVVD) announced additional initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal
Via
Benzinga
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
July 17, 2023
From
Invivyd
Via
GlobeNewswire
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
July 07, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
June 26, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19
June 22, 2023
Invivyd Inc (NASDAQ: IVVD) announces initial data from its ongoing Phase 1 healthy volunteer clinical trial of VYD222, its investigational monoclonal
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.